Dyne Therapeutics Stock Performance
| DYN Stock | USD 16.68 0.46 2.68% |
The firm shows a Beta (market volatility) of 0.55, which means possible diversification benefits within a given portfolio. As returns on the market increase, Dyne Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dyne Therapeutics is expected to be smaller as well. At this point, Dyne Therapeutics has a negative expected return of -0.11%. Please make sure to confirm Dyne Therapeutics' information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Dyne Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Dyne Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (2.68) | Five Day Return (2.40) | Year To Date Return (9.84) | Ten Year Return (30.21) | All Time Return (30.21) |
1 | Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | 12/11/2025 |
2 | Insider Trading | 12/22/2025 |
3 | Rare disease veteran joins biotech board before possible 2027 launch - Stock Titan | 12/23/2025 |
4 | First Week of February 2026 Options Trading For Dyne Therapeutics - Nasdaq | 12/29/2025 |
5 | Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference - TipRanks | 01/12/2026 |
6 | Is Dyne Therapeutics Late-Stage DMD Progress Redefining Its Rare Disease Investment Story | 01/15/2026 |
7 | Where Will Vistra Stock Be in 1 Year | 01/16/2026 |
8 | Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen for Myotonic Dystrophy Type 1 | 01/20/2026 |
9 | Disposition of 10000 shares by Cox John of Dyne Therapeutics subject to Rule 16b-3 | 02/06/2026 |
| Begin Period Cash Flow | 123.9 M | |
| Total Cashflows From Investing Activities | -204.1 M | |
| Free Cash Flow | -294.7 M |
Dyne Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,879 in Dyne Therapeutics on November 14, 2025 and sell it today you would lose (211.00) from holding Dyne Therapeutics or give up 11.23% of portfolio value over 90 days. Dyne Therapeutics is generating negative expected returns assuming volatility of 4.2948% on return distribution over 90 days investment horizon. In other words, 38% of stocks are less volatile than Dyne, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Dyne Therapeutics Target Price Odds to finish over Current Price
The tendency of Dyne Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 16.68 | 90 days | 16.68 | under 95 |
Based on a normal probability distribution, the odds of Dyne Therapeutics to move above the current price in 90 days from now is under 95 (This Dyne Therapeutics probability density function shows the probability of Dyne Stock to fall within a particular range of prices over 90 days) .
Dyne Therapeutics Price Density |
| Price |
Predictive Modules for Dyne Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dyne Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dyne Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dyne Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Dyne Therapeutics is not an exception. The market had few large corrections towards the Dyne Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Dyne Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Dyne Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.1 | |
β | Beta against Dow Jones | 0.55 | |
σ | Overall volatility | 1.44 | |
Ir | Information ratio | -0.03 |
Dyne Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dyne Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dyne Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dyne Therapeutics generated a negative expected return over the last 90 days | |
| Dyne Therapeutics has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (317.42 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne Therapeutics has about 291.84 M in cash with (292.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Dyne Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen for Myotonic Dystrophy Type 1 |
Dyne Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Dyne Stock often depends not only on the future outlook of the current and potential Dyne Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dyne Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 94.1 M | |
| Cash And Short Term Investments | 642.3 M |
Dyne Therapeutics Fundamentals Growth
Dyne Stock prices reflect investors' perceptions of the future prospects and financial health of Dyne Therapeutics, and Dyne Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dyne Stock performance.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 2.07 B | ||||
| Shares Outstanding | 164.65 M | ||||
| Price To Earning | 35.58 X | ||||
| Price To Book | 3.97 X | ||||
| EBITDA | (315.18 M) | ||||
| Net Income | (317.42 M) | ||||
| Cash And Equivalents | 291.84 M | ||||
| Cash Per Share | 5.64 X | ||||
| Total Debt | 23.99 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.63 X | ||||
| Book Value Per Share | 4.85 X | ||||
| Cash Flow From Operations | (292.37 M) | ||||
| Earnings Per Share | (3.52) X | ||||
| Market Capitalization | 2.75 B | ||||
| Total Asset | 691.23 M | ||||
| Retained Earnings | (949.93 M) | ||||
| Working Capital | 617.02 M | ||||
| Current Asset | 1.93 B | ||||
| Current Liabilities | 809 M | ||||
About Dyne Therapeutics Performance
By examining Dyne Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Dyne Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Dyne Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.86 | 48.73 | |
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.58) | (0.61) |
Things to note about Dyne Therapeutics performance evaluation
Checking the ongoing alerts about Dyne Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dyne Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dyne Therapeutics generated a negative expected return over the last 90 days | |
| Dyne Therapeutics has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (317.42 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne Therapeutics has about 291.84 M in cash with (292.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Dyne Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen for Myotonic Dystrophy Type 1 |
- Analyzing Dyne Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dyne Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dyne Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dyne Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dyne Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dyne Therapeutics' stock. These opinions can provide insight into Dyne Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Dyne diversify its offerings? Factors like these will boost the valuation of Dyne Therapeutics. Projected growth potential of Dyne fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dyne Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dyne Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dyne Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.